RxDoctor Payments Data

Barbara Karcher, MD

Internal Medicine · Petal, MSNPI 1558756387

Payments from drug & device makers

$1,492in general payments, 2019–2025

Across 89 payments — averaging $16.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$205
  • AbbVie$204
  • GSK$135
  • Amgen$128
  • Novo Nordisk$109
  • Johnson & Johnson$99
  • plus $611 from 19 others

What the payments were for

  • Food & beverage$1,492100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,492 in reported general payments places this provider in the 70th percentile of 846 internal medicine providers in Mississippi.

See all internal medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$186,732
Medicare patients
388
Services billed
3,051

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide117$142,098
OzempicSemaglutide137$136,821
JardianceEmpagliflozin114$96,516
Trelegy ElliptaFluticasone/Umeclidin/Vilanter75$55,016
JanuviaSitagliptin Phosphate56$51,974
LinzessLinaclotide41$41,782
EliquisApixaban34$40,514
XareltoRivaroxaban33$27,498
FarxigaDapagliflozin Propanediol19$16,900
ShingrixVaricella-Zoster Ge/As01b/Pf69$15,801
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$12,047
JentaduetoLinagliptin/Metformin Hcl12$5,900
Breo ElliptaFluticasone/Vilanterol11$5,872
Amlodipine-ValsartanAmlodipine Besylate/Valsartan36$5,047
Albuterol Sulfate HfaAlbuterol Sulfate127$4,838

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$205$142,098117 claims
Novo NordiskOzempic, Novolog$109$140,065149 claims
Boehringer IngelheimJardiance, Jentadueto$47$102,415126 claims
GSKTrelegy Ellipta, Shingrix, Breo Ellipta$135$76,690155 claims
AbbVieLinzess, Synthroid$204$46,523107 claims
PfizerEliquis$74$40,51434 claims
AstraZenecaFarxiga, Breztri Aerosphere$16$28,94736 claims
Johnson & JohnsonXarelto$99$27,49833 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 846 internal medicine providers in Mississippi.

Other internal medicine in Petal

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →